The research team, led by Francine R. Vega and colleagues at the McWilliams School of Biomedical Informatics at the University of Texas Health Science Center at Houston, conducted a cross-sectional, anonymous online survey of physicians, nurse practitioners, and physician assistants who were authorized to prescribe opioids or medications for opioid use disorder and were actively providing pediatric care. Using snowball sampling, the investigators recruited participants across the United States and measured five domains: awareness of relevant laws, clinical knowledge, prescribing confidence, concerns about parental consent, and beliefs about medications for opioid use disorder, often abbreviated as MOUD.

The headline finding is a striking paradox. Prescribers who had never given buprenorphine to an adolescent actually claimed higher awareness of the laws governing under-18 prescribing, with 94.2 percent reporting awareness compared with 86.7 percent of those who had prescribed. Yet the non-prescribers were simultaneously more uncertain about what those laws actually meant in practice. For example, 32.3 percent of non-prescribers were unsure whether their state restricts buprenorphine prescribing to minors, compared with 26.5 percent of prescribers, a difference that was statistically significant. In other words, knowing that rules exist is not the same as knowing what they allow.

To quantify these relationships, the researchers compared responses between the two groups using chi-square tests with Monte Carlo estimation, a computational technique that produces reliable significance values when survey data do not fit standard statistical assumptions. They then built a multivariable logistic regression model, adjusting for clinician type, practice setting, years in practice, and other characteristics, and reported the results as odds ratios with 95 percent confidence intervals. This approach allowed the team to isolate which factors independently predicted whether a clinician had ever prescribed buprenorphine for adolescent opioid use disorder.

The adjusted results were revealing. Greater legal clarity roughly two and a half times the odds of having prescribed buprenorphine to an adolescent (OR 2.58, 95 percent CI 1.13 to 5.98). Male gender was also associated with higher odds (OR 1.64, 95 percent CI 1.16 to 2.33), as was reporting parental consent as a barrier, a counterintuitive finding that the authors suggest may reflect engagement: clinicians who have wrestled with consent requirements in real cases are more likely to have prescribed despite them. Meanwhile, working in an office-based group practice (OR 0.52) and certain career stages, including fewer than five years in practice (OR 0.53) and 16 to 20 years in practice (OR 0.55), were associated with lower odds compared with solo practice and the five-to-ten-year reference group.

Notably, the type of clinician mattered less than the environment in which that clinician worked. The study found that prescribing history was more strongly associated with legal clarity, practice characteristics, and beliefs about MOUD than with whether the respondent was a physician, nurse practitioner, or physician assistant. That distinction carries real policy weight. If the barrier were professional training alone, the solution would be more education for one cadre of providers. Because the barrier appears to be regulatory ambiguity and practice-level norms, the solution lies in clearer guidance and institutional support that reaches every prescribing profession.

The clinical stakes are considerable. Opioid-related morbidity and mortality among adolescents continue to rise, driven largely by illicit fentanyl contaminating counterfeit pills. Buprenorphine, a partial opioid agonist that suppresses withdrawal and cravings, has strong evidence of effectiveness and is endorsed by professional societies, including the American Academy of Pediatrics, for adolescents with opioid use disorder. Yet pediatric settings remain among the least likely places for a young person to start this medication, which means many adolescents cycle through emergency departments or drop out of care entirely without ever being offered a treatment that could save their lives.

Parental consent is a uniquely pediatric complication. Unlike adult addiction medicine, where treatment can begin with the patient’s own consent, adolescent care is governed by a patchwork of state laws on minor consent, confidentiality, and mandatory parental notification. Some states permit minors to consent to substance use treatment on their own; others require parental involvement; many leave the boundaries vague. A clinician who cannot quickly determine what their state allows may default to inaction, especially in busy primary care or emergency settings where there is no time for legal research. The survey’s finding that perceived consent barriers correlate with prescribing history suggests these concerns are woven into daily decision-making rather than being abstract worries.

The authors frame their conclusions carefully, acknowledging that the sample was a non-probability sample recruited through snowball sampling, which means the respondents may not represent all US pediatric prescribers and the results describe associations rather than causes. Still, the pattern they identified points to concrete, modifiable targets. Clarifying state-level rules, issuing practical guidance on consent and confidentiality for minor patients, and addressing normative beliefs about medications for opioid use disorder within group practices could all lower the threshold for a first prescription. Because the study received no external funding and was approved by the University of Texas Health Science Center institutional review board, with informed consent obtained from all participants, it offers an unusually transparent window into a workforce decision that has been difficult to measure.

The broader lesson extends beyond buprenorphine. When the law is ambiguous, clinicians behave conservatively, and that conservatism falls hardest on the patients with the least power to advocate for themselves, including minors with a stigmatized, life-threatening condition. This survey of 600 American pediatric prescribers shows that the gap between evidence and practice is not primarily a knowledge gap. It is a clarity gap, and closing it may be one of the fastest available ways to get evidence-based treatment to adolescents who are dying for lack of it.

Subject of Research: Legal and practice barriers to buprenorphine prescribing for adolescents with opioid use disorder among US pediatric prescribers

Article Title: Legal and other barriers to buprenorphine prescribing for adolescents with opioid use disorder: a provider survey

Article References: Vega, F. R., Champagne-Langabeer, T., Cohen, A. S., Vijendra, R., Langabeer, J. R., Yatsco, A., & Bakos-Block, C. (2026). Legal and other barriers to buprenorphine prescribing for adolescents with opioid use disorder: a provider survey. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07582-z

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07582-z

Keywords: buprenorphine, opioid use disorder, adolescents, pediatric prescribers, medications for opioid use disorder, legal barriers, parental consent, prescribing practices, provider survey, BMC Pediatrics, MOUD, opioid crisis